| DC66599 |
β-D-Glucopyranosiduronic acid, tetradecyl
Featured
|
|
|
| DC66600 |
BLU-222
Featured
|
BLU-222 is an investigational, oral, potent, and selective CDK2 inhibitor. BLU-222 has shown robust anti-tumor activity in preclinical models of CCNE-aberrant ovarian, breast and gastric cancer. |
|
| DC66601 |
Zoniporide
Featured
|
|
|
| DC66602 |
Gepotidacin mesylate
Featured
|
Gepotidacin, also known as GSK-2140944, is a potent Type II DNA topoisomerase inhibitor. Gepotidacin is a novel antibacterial drug candidate. Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively. |
|
| DC66603 |
IWY357
Featured
|
|
|
| DC66604 |
EOS-984
Featured
|
|
|
| DC66605 |
NDI-101150
Featured
|
NDI-101150 is a highly selective, orally bioavailable small-molecule inhibitor targeting hematopoietic progenitor kinase 1 (HPK1/MAP4K1), a key negative regulator of T-cell signaling. This compound demonstrates potent immunomodulatory activity by enhancing T-cell activation and proliferation, while simultaneously exhibiting robust antitumor efficacy in preclinical models. Its mechanism of action involves disrupting HPK1-mediated suppression of immune responses, leading to improved T-cell function and sustained inhibition of tumor progression. With its favorable pharmacokinetic profile and specificity for HPK1, NDI-101150 represents a promising therapeutic candidate for cancer immunotherapy, particularly in settings where T-cell activity is compromised. |
|
| DC66606 |
TYRA-300
Featured
|
TYRA-300 is the first oral selective FGFR3 inhibitor with IC50 of 11 nM in Ba/F3 cells, and shows selectivity over FGFR1, FGFR2 and FGFR4 in Ba/F3 cells was 25-, 14-, and 36-fold, respectively. TYRA-300 demonstrates equivalent potency for FGFR3 WT and V555M/L gatekeeper mutations in enzymatic assays and in engineered RT112/84 and UM-UC-14 bladder cancer cell lines containing the V555M mutation. |
|
| DC66607 |
BAY2925976
Featured
|
|
|
| DC66608 |
BMS-986397
Featured
|
|
|
| DC66609 |
PLX-4545
Featured
|
|
|
| DC66610 |
Castadifan
Featured
|
|
|
| DC66611 |
PF-07328948
Featured
|
|
|
| DC66612 |
VVD-130037
Featured
|
VVD-130037 is an oral covalent activator of KEAP/NRF2 degrader. |
|
| DC66613 |
BMS-986308
Featured
|
BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research. |
|
| DC60636 |
Acid-degradable Cationic Lipid (ADC)
Featured
|
Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo. |
.png)
|
| DC60637 |
BI-9508
Featured
|
BI-9508 is a potent and selective, brain-penetrant GPR88 agonist with EC50 of 47 nM. |
|
| DC66614 |
Vc-seco-duba
Featured
|
Vc-seco-DUBA (SYD985) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco. |
|
| DC66615 |
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br
Featured
|
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br is an ADC linker that can be used to synthesize ABBV-154, ABBV-927, ABBV-368 or their analogs. |
|
| DC66616 |
Sulfo-PDBA-DM4
Featured
|
Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker. |
|
| DC66617 |
Mal-amido-PEG6-NHS ester
Featured
|
Mal-amido-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. |
|
| DC66618 |
4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid DIEA Salt
Featured
|
|
|
| DC66619 |
Val-Ala-PAB
Featured
|
Val-Ala-PAB is a cleavable ADC linker that can be used for ADCs synthesis. |
|
| DC66620 |
Fomc-Gly-Gly-Phe-Gly-OH
Featured
|
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit. |
|
| DC66621 |
Fmoc-GGFL-OH
Featured
|
|
|
| A050 |
Licaminlimab Biosimilar(Anti-TNFSF2 / TNFa Reference Antibody )
Featured
|
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation. |
|
| A051 |
Gremubamab Biosimilar (Anti-PcrV Reference Antibody )
Featured
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections. |
|
| A052 |
Nirsevimab Biosimilar (Anti-RSV Reference Antibody)
Featured
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections. |
.png)
|
| A053 |
Aselizumab Biosimilar (Anti-L-selectin Reference Antibody)
Featured
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma. |
.png)
|
| A054 |
Raxibacumab Biosimilar（Anti-PA Reference Antibody）
Featured
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research. |
.png)
|
